Halper Sadeh LLC is investigating Know Labs, Elevation Oncology, and Crown Electrokinetics regarding potential securities law breaches. This could impact shareholders significantly.

Halper Sadeh LLC is examining potential federal securities law violations by Flowserve, Know Labs, Elevation Oncology, and Crown Electrokinetics.

Elevation Oncology has announced its merger with Concentra Biosciences, promising new developments in cancer therapies. This strategic move is expected to enhance shareholder value.

Elevation Oncology has shared its first quarter 2025 financial results, highlighting progress in HER3 ADC EO-1022 development and strategic options to enhance shareholder value.

Elevation Oncology shared compelling preclinical data for EO-1022 at AACR 2025, showcasing its potential as a HER3 ADC in treating solid tumors.

Elevation Oncology announces the discontinuation of EO-3021 development while channeling efforts into EO-1022, as it evaluates strategic options for shareholder value.

Elevation Oncology announces significant financial outcomes for Q4 and the entirety of 2024, along with major achievements in its cancer treatment programs.

Elevation Oncology has made significant strides in its clinical trials for innovative ADC therapies aimed at treating advanced gastric cancer, with promising results expected soon.

Elevation Oncology has introduced EO-1022, a HER3 ADC aimed at treating solid tumors. This novel candidate showcases advanced technologies for potential cancer therapy breakthroughs.

Elevation Oncology has secured a licensing agreement with Synaffix for innovative ADC technology to boost their drug development pipeline targeting solid tumors.

Elevation Oncology has presented preclinical data for EO-3021 demonstrating significant anti-tumor effects when combined with VEGFR2 or PD-1 inhibitors, promising new treatment avenues.